Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

Faculty Information

We are honored that you have agreed to be part of the faculty for the EHA-ISHBT Hematology Tutorial, to be held on March 1-3, 2024 in Hyderabad, India.

Read more

SWG Educational Activities

Social and public activitiesSince 2020, Prof Hermann Einsele has been a Councilor to the EHA Board. Scientific activitiesFifth European CAR T-cell meetingDateFebruary 9–11, 2023. LocationRotterdam, The Netherlands.

Read more

La Cantera coaching

Disease-orientated training courses for young clinicians and researchers, inspired by a world-renowned football academy model. Call for interest from SWGs
In 2025, EHA will fund an additional course based on the La Cantera model.

Read more

Choose your membership

Wherever you are in the world, you can join our vibrant community and benefit from our rigorous resources and career-enhancing opportunities.

Read more

Privacy statement

May 21, 2021

Privacy Statement European Hematology Association

Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).

Read more

GoCART Coalition - Call for research proposals within Work Package 6: Scientific Excellence

Dear GoCART community, 

With more than 1500 CAR-T infusions registered in the EBMT registry, EHA and EBMT are proud to announce a series of scientific calls within Work Package 6: Scientific Excellence of the GoCART coalition.

Read more